๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Wuhan
Clinical trial register · China

Clinical Trials in Wuhan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 24 Guangzhou 23 Shanghai 22 Wuhan 14 Chongqing 13
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing24 Guangzhou23 Shanghai22 Wuhan14 Chongqing13
All 50 locations
Target enrolment
to

Trials with a site in Wuhan

14 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Prospective Sample Collection Study for a Blood-Based cfDNA Methylation Assay for Ovarian Cancer Detection
NCT07593833Ovarian Neoplasms, Ovarian Cancer, Early Detection of Cancer
Tongji Hospital
Observational
1,000
Wuhan
2026-07-01
Not yet open
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer
NCT06990503Ovarian Cancer
Tongji Hospital
Phase 3
300
Wuhan
2025-06-01
Not yet open
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer
NCT06990516Ovarian Cancer
Tongji Hospital
Phase 1/2
90
Wuhan
2025-06-01
Recruiting
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
NCT06840002Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
150
Wuhan
2025-03-18
Recruiting
A Study of SHR-A1811 in Subjects With Ovarian Cancer
NCT06828354Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
300
Wuhan, Jinan
2025-03-13
Recruiting
Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
NCT06843629Ovarian Cancer, Lung Adenocarcinoma, Pancreatic Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
100
Wuhan
2024-10-01
Active, closed
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
NCT06380660Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
Acerand Therapeutics (Shanghai) Limited
Phase 1/2
298
Chongqing, Fuzhou, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha, Jinan
2024-03-22
Active, closed
A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer
NCT06483425Ovarian Cancer, Biomarker
Tongji Hospital
Observational
2,000
Wuhan
2024-03-01
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
AbbVie
Phase 3
520
Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-03-15
Recruiting
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer
AstraZeneca
Phase 2
454
Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan
2022-09-06
Recruiting
A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer
NCT05206890Ovarian Cancer
Tongji Hospital
Observational
490
Wuhan
2022-01-14
Active, closed
Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
NCT04507841Ovarian Cancer
Tongji Hospital
Phase 2
67
Wuhan
2021-01-08
Recruiting
APG-2449 in Patients With Advanced Solid Tumors
NCT03917043Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer
Ascentage Pharma Group Inc.
Phase 1
165
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou
2019-05-27
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/wuhan

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies with a site in Wuhan that also match the filters currently applied.

How many clinical trials are recruiting in Wuhan?

7 of the 14 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Wuhan), 14 studies
PhaseStudiesRecruitingShare
Observational4228.6%
Phase 34228.6%
Phase 1/23121.4%
Phase 22114.3%
Phase 1117.1%

Most active sponsors

Lead sponsors with the most studies (Wuhan)
Lead sponsorStudiesRecruiting
Tongji Hospital72
AbbVie10
Acerand Therapeutics (Shanghai) Limited10
Ascentage Pharma Group Inc.11
AstraZeneca11
Jiangsu HengRui Medicine Co., Ltd.11
Suzhou Suncadia Biopharmaceuticals Co., Ltd.11
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.